Randomized controlled trial· 2021
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Lau DCW, Erichsen L, Francisco AM, et al.
The Lancet
- PubMed
- 34798060
- Evidence level
- moderate
- Verification
- verified
Summary
Phase 2 dose-finding trial comparing once-weekly cagrilintide doses with placebo and open-label liraglutide in adults with overweight or obesity without diabetes.
Limitations
The study was phase 2, treatment lasted 26 weeks and the active comparator was open label. Longer-term safety, durability and clinical outcomes were not established.